WHEN TO BEGIN COMBINED THERAPY OF TYPE 2 DIABETES MELLITUS
- Autores: Petunina NA1, Petunina N.A.1
-
Afiliações:
- Edição: Nº 16 (2010)
- Páginas: 53-59
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278641
- ID: 278641
Citar
Texto integral
Resumo
Type 2 diabetes mellitus (DM2) is disease caused by insulin resistance and relative insulin deficiency. The article is dedicated to the modern principles of treatment of DM2 and hypoglycemic agents. One of the frequently used hypoglycemic agents is metformin, which can be combined with sulfonylureas in the case of ineffectiveness of treatment of DM2. The potentials for the use of Glucovance, combined tableted drug consisting of metformin and glibenclamide are discussed. Micronised form of glibenclamide in the Glucovance ensures the safety of the drug with high efficiency. This drug has less effect on β-cells, does not increase the fasting plasma insulin concentration, and reduces the risk of hypoglycemia. Affordability of Glucovance is important.
Bibliografia
- Дедов И.И., Шестакова М.В. Сахарный диабет. Руководство для врачей. М., 2003.
- Кононенко И.В., Смирнова О.М. Роль Глюкованса в патогенетическом лечении сахарного диабета 2 типа // РМЖ. 2006. Т. 14. № 13. С. 945-50.
- Blonde L, et al. Glyburide/metformine product in safe and efficacious is patients with type 2 diabetes failing sulphonylurea. Diab Ob Metab 2002;4:368-74.
- Dailey GE. Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes. Expert Opin Pharmacother 2003;4(8):1417-30.
- DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
- Donahue S, et al. Pharmacokinetics and pharmacodynamics of a combination glyburide/metformin tablet versus equivalent doses of glyburide + metformin in patients with type 2 diabetes. Endocr Pract 2002;8:149.
- Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: An open-label extension study. Clin Ther 2002;24:1401-13.
- Howlett H, Porte F, Allavoine T, et al. The Development of an Oral Antidiabetic Combination Tablet: Design, Evaluation and Clinical Benefits for Patients with Type 2 Diabetes. Curr Med Res Opin 2003;19(3):218-25.
- Marrе M, et al. Improved glycaemic control with metformin-glibenclamide combined tabtet therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19:673-80.
- Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet 2002;41(15):1301-09.
Arquivos suplementares
